Listed

Celldex Therapeutics, Inc.

CLDXNasdaqCIK 744218HealthcareFiscal year ends Dec 31

Reports and events: 261 filings

Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.

What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.

Celldex Therapeutics, Inc., Reports and events
FiledFormWhat it isAccession number
2016-02-2508:20 ET10-K/AAnnual report, amendedPeriod 2015-12-310001047469-16-010396
2016-02-2507:00 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-16-008122
2016-02-2316:39 ET8-K8.01 Other events0001104659-16-099219
2016-02-2310:13 ET10-KAnnual reportPeriod 2015-12-310001047469-16-010308
2015-11-0517:01 ET10-QQuarterly reportPeriod 2015-09-300001104659-15-076295
2015-11-0516:50 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-15-006067
2015-08-1016:10 ET10-QQuarterly reportPeriod 2015-06-300001104659-15-058233
2015-08-1016:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-15-004515
2015-06-1111:21 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001104659-15-044791
2015-04-2908:29 ET10-QQuarterly reportPeriod 2015-03-310001104659-15-031298
2015-04-2908:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-15-002279
2015-04-2309:56 ETDEF 14AProxy statementPeriod 2015-06-100001047469-15-003819
2015-02-2606:05 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001104659-15-014023
2015-02-2408:31 ET10-KAnnual reportPeriod 2014-12-310001047469-15-001081
2015-02-2407:45 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001104659-15-013213
2014-12-1808:01 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001171843-14-005945
2014-11-0616:03 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001104659-14-077686
2014-11-0509:09 ET10-QQuarterly reportPeriod 2014-09-300001104659-14-076822
2014-11-0416:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-14-005224
2014-10-2009:00 ET8-K1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits0001104659-14-072365
2014-08-0709:01 ET10-QQuarterly reportPeriod 2014-06-300001104659-14-057922
2014-08-0616:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-14-003761
2014-05-2909:53 ET8-K5.07 Shareholder vote results0001104659-14-042206
2014-05-1408:30 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001104659-14-038370
2014-05-0108:50 ET10-QQuarterly reportPeriod 2014-03-310001104659-14-033059
2014-05-0108:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-14-002068
2014-04-0909:01 ETDEF 14AProxy statementPeriod 2014-05-280001047469-14-003582
2014-04-0809:16 ET8-K5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits0001104659-14-026295
2014-03-0311:36 ET10-KAnnual reportPeriod 2013-12-310001047469-14-001653
2014-03-0308:03 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-14-001050
2013-12-0507:02 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001104659-13-088493
2013-11-2508:11 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-13-086729
2013-11-2506:02 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-13-086714
2013-11-0809:47 ET10-QQuarterly reportPeriod 2013-09-300001104659-13-082619
2013-11-0808:03 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001171843-13-004514
2013-08-0610:03 ET10-QQuarterly reportPeriod 2013-06-300001104659-13-060226
2013-06-1308:30 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001104659-13-048808
2013-05-2008:25 ET8-K1.02 Termination of a material agreement0001104659-13-043025
2013-05-0308:51 ET10-QQuarterly reportPeriod 2013-03-310001104659-13-036833
2013-05-0208:36 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001104659-13-036266
2013-04-2308:17 ETDEF 14AProxy statementPeriod 2013-06-120001047469-13-004692
2013-03-0812:53 ET10-KAnnual reportPeriod 2012-12-310001047469-13-002403
2013-03-0708:10 ET8-K2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits0001104659-13-018165
2013-02-0606:01 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001104659-13-007717
2013-02-0416:04 ET8-K8.01 Other events0001104659-13-007111
2013-01-0708:01 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-13-000878
2012-12-2108:00 ET8-K5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001104659-12-085680
2012-11-0208:14 ET10-QQuarterly reportPeriod 2012-09-300001104659-12-073441
2012-11-0108:32 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001157523-12-005610
2012-09-2408:05 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001104659-12-064917

Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.